Quinoline-derived SARS-CoV-2 papain-like protease inhibitors are oral antiviral drug candidates
​
A lead compound, the quinoline-derived PLpro inhibitor Jun13296, demonstrates substantial protection against SARS-CoV-2 infection and adverse clinical outcomes.
Invention Summary:
The COVID-19 pandemic significantly accelerated the development of antiviral therapies and vaccines. Recent efforts for research to support pandemic preparedness...
Published: 7/31/2025
|
Inventor(s): Jun Wang, Prakash Jadhav, Bin Tan, Haozhou Tan
Keywords(s): Antiviral
Category(s): Technology Classifications > COVID-19, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics
|